Investing
FDA rejects Mesoblast’s cell therapy for bone marrow transplant complications
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo/File Photo
(Reuters) – The U.S. Food and Drug Administration had rejected Mesoblast (NASDAQ:)’s cell therapy for children under 12 years of age for treating a type of complication that occurs after a stem cell or bone marrow transplant, the company said on Thursday.
The health regulator required more data to support marketing approval for the company’s lead product remestemcel-L, Mesoblast said in a statement.
The rejection deals a blow to Mesoblast’s hopes for a potential launch of the therapy, especially after its fundraising efforts over the last two years.
The drug developer was seeking the FDA’s approval for a cell therapy to treat children with a type of graft versus host disease (GvHD), whose symptoms did not respond to standard steroid therapy or developed recurrence while continuing treatment.
There are no approved therapies in children for the condition in which the donor bone marrow or stem cells attack the recipient.
Read the full article here
-
Investing6 days ago
Hurricane Helene Hits Spruce Pine Mine, Quartz Used for Tech
-
Side Hustles7 days ago
5 Key Strategies for a Seamless Cloud Migration
-
Investing7 days ago
Israel stocks lower at close of trade; TA 35 down 0.23% By Investing.com
-
Side Hustles6 days ago
VP Exec’s Top Tips for Negotiating and Relationship-Building
-
Passive Income7 days ago
Go Paperless with the PDF Reader Pro for $49.99
-
Investing5 days ago
U.K. stocks lower at close of trade; Investing.com United Kingdom 100 down 1.37% By Investing.com
-
Side Hustles7 days ago
Why the Future of Cybersecurity Marketing Relies on Trust
-
Side Hustles6 days ago
Why the Smallest Details Mean the Most in Marketing